| Methods |
RCT comparing oral rivaroxaban versus enoxaparin for the treatment of symptomatic pulmonary embolism. |
| Data |
4833 patients were randomised (2420/2413, respectively in each treatment group). |
| Comparisons |
Onsite assessment (local investigator non blinded) versus assessment by an AC blinded to allocated treatment. |
| Outcomes |
The outcome selected was recurrent venous thromboembolism. It was the study's primary outcome. |
| Notes |
Data related to the number of events in each treatment group resulting from onsite‐assessment were obtained directly from the study authors. |
| Risk of bias |
| Item |
Authors' judgement |
Description |
| Method for selecting cases to adjudicate? |
Yes |
All suspect events adjudicated were identified by onsite assessor who was not blinded to allocated treatment. |
